NAGE Quote, Financials, Valuation and Earnings

Corcept Therapeutics, Inc. has a net margin of 12.21% compared to Niagen Bioscience, Inc.'s net margin of 11.83%. Niagen Bioscience, Inc.'s return on equity of 27.78% beat Corcept Therapeutics, Inc.'s return on equity of 14.97%.

Niagen Bioscience, Inc. has a consensus price target of $13.60, signalling upside risk potential of 210.5%. On the other hand Corcept Therapeutics, Inc. has an analysts' consensus of $67.40 which suggests that it could grow by 58.63%. Given that Niagen Bioscience, Inc. has higher upside potential than Corcept Therapeutics, Inc., analysts believe Niagen Bioscience, Inc. is more attractive than Corcept Therapeutics, Inc..

Niagen Bioscience, Inc. has a beta of 2.235, which suggesting that the stock is 123.522% more volatile than S&P 500. In comparison Corcept Therapeutics, Inc. has a beta of 0.249, suggesting its less volatile than the S&P 500 by 75.089%.

Niagen Bioscience, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Corcept Therapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Niagen Bioscience, Inc. pays -- of its earnings as a dividend. Corcept Therapeutics, Inc. pays out -- of its earnings as a dividend.

Niagen Bioscience, Inc. quarterly revenues are $33.8M, which are smaller than Corcept Therapeutics, Inc. quarterly revenues of $202.1M. Niagen Bioscience, Inc.'s net income of $4.1M is lower than Corcept Therapeutics, Inc.'s net income of $23.9M. Notably, Niagen Bioscience, Inc.'s price-to-earnings ratio is 21.44x while Corcept Therapeutics, Inc.'s PE ratio is 52.54x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Niagen Bioscience, Inc. is 2.88x versus 6.77x for Corcept Therapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Nephros, Inc. has a net margin of 12.21% compared to Niagen Bioscience, Inc.'s net margin of 1.31%. Niagen Bioscience, Inc.'s return on equity of 27.78% beat Nephros, Inc.'s return on equity of 12.52%.

Niagen Bioscience, Inc. has a consensus price target of $13.60, signalling upside risk potential of 210.5%. On the other hand Nephros, Inc. has an analysts' consensus of $7.00 which suggests that it could grow by 143.9%. Given that Niagen Bioscience, Inc. has higher upside potential than Nephros, Inc., analysts believe Niagen Bioscience, Inc. is more attractive than Nephros, Inc..

Niagen Bioscience, Inc. has a beta of 2.235, which suggesting that the stock is 123.522% more volatile than S&P 500. In comparison Nephros, Inc. has a beta of 1.558, suggesting its more volatile than the S&P 500 by 55.755%.

Niagen Bioscience, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Nephros, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Niagen Bioscience, Inc. pays -- of its earnings as a dividend. Nephros, Inc. pays out -- of its earnings as a dividend.

Niagen Bioscience, Inc. quarterly revenues are $33.8M, which are larger than Nephros, Inc. quarterly revenues of $4.7M. Niagen Bioscience, Inc.'s net income of $4.1M is higher than Nephros, Inc.'s net income of $62K. Notably, Niagen Bioscience, Inc.'s price-to-earnings ratio is 21.44x while Nephros, Inc.'s PE ratio is 25.18x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Niagen Bioscience, Inc. is 2.88x versus 1.62x for Nephros, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

SIGA Technologies, Inc. has a net margin of 12.21% compared to Niagen Bioscience, Inc.'s net margin of -143.11%. Niagen Bioscience, Inc.'s return on equity of 27.78% beat SIGA Technologies, Inc.'s return on equity of 11.15%.

Niagen Bioscience, Inc. has a consensus price target of $13.60, signalling upside risk potential of 210.5%. On the other hand SIGA Technologies, Inc. has an analysts' consensus of -- which suggests that it could fall by --. Given that Niagen Bioscience, Inc. has higher upside potential than SIGA Technologies, Inc., analysts believe Niagen Bioscience, Inc. is more attractive than SIGA Technologies, Inc..

Niagen Bioscience, Inc. has a beta of 2.235, which suggesting that the stock is 123.522% more volatile than S&P 500. In comparison SIGA Technologies, Inc. has a beta of 1.049, suggesting its more volatile than the S&P 500 by 4.923%.

Niagen Bioscience, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. SIGA Technologies, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.60 per share. Niagen Bioscience, Inc. pays -- of its earnings as a dividend. SIGA Technologies, Inc. pays out -- of its earnings as a dividend.

Niagen Bioscience, Inc. quarterly revenues are $33.8M, which are larger than SIGA Technologies, Inc. quarterly revenues of $3.8M. Niagen Bioscience, Inc.'s net income of $4.1M is higher than SIGA Technologies, Inc.'s net income of -$5.4M. Notably, Niagen Bioscience, Inc.'s price-to-earnings ratio is 21.44x while SIGA Technologies, Inc.'s PE ratio is 16.41x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Niagen Bioscience, Inc. is 2.88x versus 4.03x for SIGA Technologies, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Verastem, Inc. has a net margin of 12.21% compared to Niagen Bioscience, Inc.'s net margin of -187.72%. Niagen Bioscience, Inc.'s return on equity of 27.78% beat Verastem, Inc.'s return on equity of -6385.92%.

Niagen Bioscience, Inc. has a consensus price target of $13.60, signalling upside risk potential of 210.5%. On the other hand Verastem, Inc. has an analysts' consensus of $16.38 which suggests that it could grow by 190.85%. Given that Niagen Bioscience, Inc. has higher upside potential than Verastem, Inc., analysts believe Niagen Bioscience, Inc. is more attractive than Verastem, Inc..

Niagen Bioscience, Inc. has a beta of 2.235, which suggesting that the stock is 123.522% more volatile than S&P 500. In comparison Verastem, Inc. has a beta of 0.432, suggesting its less volatile than the S&P 500 by 56.809%.

Niagen Bioscience, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Verastem, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Niagen Bioscience, Inc. pays -- of its earnings as a dividend. Verastem, Inc. pays out -- of its earnings as a dividend.

Niagen Bioscience, Inc. quarterly revenues are $33.8M, which are larger than Verastem, Inc. quarterly revenues of $17.5M. Niagen Bioscience, Inc.'s net income of $4.1M is higher than Verastem, Inc.'s net income of -$32.9M. Notably, Niagen Bioscience, Inc.'s price-to-earnings ratio is 21.44x while Verastem, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Niagen Bioscience, Inc. is 2.88x versus 13.14x for Verastem, Inc.. Usually stocks with elevated PS ratios are considered overvalued.